Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review

##plugins.themes.academic_pro.article.sidebar##

Published Nov 9, 2025
https://doi.org/10.62438/tunismed.v103i9.6339
Download
pdf
Vol. 103 No. 9 (2025): Tunis Med sept 2025

##plugins.themes.academic_pro.article.main##

Rim Bourguiba
Internal Medicine Department, Internal Security Forces Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis EL Manar, Tunisia
Saoussen Antit
Cardiology Department, Internal Security Forces Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis EL Manar, Tunisia
Sarra Ben Rejeb
Department of Anatomopathology, Internal Security Forces Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis EL Manar, Tunisia
Syrine Bellakhal
Internal Medicine Department, Internal Security Forces Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis EL Manar, Tunisia
Lilia Zakhama
Cardiology Department, Internal Security Forces Hospital, La Marsa, Faculty of Medicine of Tunis, University of Tunis EL Manar, Tunisia

Abstract

Introduction : Cardiac amyloidosis is an underdiagnosed cause of heart failure characterized by extracellular deposition of misfolded proteins, most commonly transthyretin (ATTR) or immunoglobulin light chains (AL). Despite recent advances in disease-modifying therapies, prognosis remains poor. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits. However, evidence regarding their safety and efficacy in cardiac amyloidosis remains limited.


 Aim: This systematic review aimed to synthesize current evidence on the clinical outcomes and safety of SGLT2 inhibitors in patients with cardiac amyloidosis.


 Methods: A comprehensive literature search was conducted in PubMed, Embase, Google Scholar, ScienceDirect, and Cochrane Library through June 2025, in accordance with PRISMA guidelines. Studies evaluating the use of SGLT2i in cardiac amyloidosis were included. Outcomes assessed were all-cause mortality, stroke, hospitalization for heart failure, and kidney failure. Data extraction and quality assessment were performed independently by two reviewers. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled when appropriate.


 Results: Five studies comprising 17,416 patients met inclusion criteria. The mean age was 76.8 years, and 78% were male. Use of SGLT2 inhibitors was associated with a significant reduction in all-cause mortality (HR 0.64; 95% CI 0.57–0.71) and stroke risk (HR 0.64; 95% CI 0.54–0.77). For hospitalization due to heart failure, there was a trend toward benefit (HR 0.88; 95% CI 0.76–1.02), though this did not reach statistical significance. The risk of kidney failure was modestly reduced (HR 0.91; 95% CI 0.71–1.08). Overall study quality was moderate.


 Conclusions: SGLT2 inhibitors appear to be a promising therapeutic option in cardiac amyloidosis, potentially improving survival and reducing cerebrovascular events while maintaining a favorable safety profile. However, current evidence is limited by observational study designs and heterogeneity. High-quality randomized controlled trials are needed to confirm these findings and guide clinical practice.


 

Keywords:

Amyloidosis, SGLT2i, cardiac amyloidosis

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. The Lancet [Internet] 2016 [cité 2025 août 3];387:2641‑54. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067361501274X
  2. Bloom MW, Gorevic PD. Cardiac Amyloidosis. Ann Intern Med [Internet] 2023 [cité 2025 août 3];176:ITC33‑48. Available from: https://www.acpjournals.org/doi/10.7326/AITC202303210
  3. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med [Internet] 2024 [cité 2025 août 3];390:132‑42. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2305434
  4. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med [Internet] 2023 [cité 2025 août 3];389:1553‑65. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2300757
  5. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med [Internet] 2021 [cité 2025 août 3];385:493‑502. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2107454
  6. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med [Internet] 2021 [cité 2025 août 3];385:46‑58. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2028631
  7. Bloom MW, Gorevic PD. Cardiac Amyloidosis. Ann Intern Med [Internet] 2023 [cité 2025 janv 4];176:ITC33‑48. Available from: https://www.acpjournals.org/doi/10.7326/AITC202303210
  8. Zampieri M, Argirò A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med [Internet] 2022 [cité 2025 mars 13];17:1243‑5. Available from: https://link.springer.com/10.1007/s11739-022-02944-8
  9. Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, et al. Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. Journal of Cardiac Failure [Internet] 2024 [cité 2025 août 3];30:1641‑6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1071916424002318
  10. Van Der Aart-van Der Beek AB, De Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol [Internet] 2022 [cité 2025 janv 4];18:294‑306. Available from: https://www.nature.com/articles/s41581-022-00535-6
  11. Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, et al. Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. Journal of Cardiac Failure [Internet] 2024 [cité 2025 janv 4];30:1641‑6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1071916424002318
  12. Steinhardt MJ, Cejka V, Chen M, Bäuerlein S, Schäfer J, Adrah A, et al. Safety and Tolerability of SGLT2 Inhibitors in Cardiac Amyloidosis—A Clinical Feasibility Study. JCM [Internet] 2024 [cité 2025 janv 4];13:283. Available from: https://www.mdpi.com/2077-0383/13/1/283
  13. Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, et al. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Failure [Internet] 2023 [cité 2025 janv 4];10:397‑404. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14188
  14. Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology [Internet] 2024 [cité 2025 janv 4];83:2411‑22. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109724069705
  15. Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, et al. Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety. European J of Heart Fail [Internet] 2024 [cité 2025 janv 4];26:938‑47. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3198
  16. Pillai A, Riaz S, Arora S, Jaiswal A. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Transthyretin Cardiac Amyloidosis: A Single-Center Retrospective Cohort Study. Cureus [Internet] 2024 [cité 2025 janv 4];Available from: https://www.cureus.com/articles/311459-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-adults-with-transthyretin-cardiac-amyloidosis-a-single-center-retrospective-cohort-study
  17. Sivamurugan A, Byer SH, Grewal US, Dominic P. Impact of SGLT2 inhibitors on the outcomes of patients with cardiac arrhythmias and transthyretin cardiac amyloidosis. Heart Rhythm [Internet] 2024 [cité 2025 janv 4];S1547527124032922. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1547527124032922
  18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet] 2021 [cité 2025 févr 9];n71. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.n71
  19. Bourguiba R, Antit S, Ben rejab sarrah, Bellakhal S, Zakhama L. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in CardiacAmyloidosis: A Systematic Review : Study protocol. La tunisie medicale2025;
  20. Wells G, Shea B, O’Connell J. The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Nonrandomised Studies in Meta-analyses. Ottawa Health Research Institute Web site 2014;7.
  21. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐randomized studies ( MINORS ): development and validation of a new instrument. ANZ Journal of Surgery [Internet] 2003 [cité 2025 sept 4];73:712‑6. Available from: https://onlinelibrary.wiley.com/doi/10.1046/j.1445-2197.2003.02748.x
  22. Schwegel N, Toferer C, Zach DK, Santner V, Höller V, Lugitsch J, et al. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. JCM [Internet] 2024 [cité 2025 mars 13];13:5966. Available from: https://www.mdpi.com/2077-0383/13/19/5966
  23. Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy. The American Journal of Cardiology [Internet] 2025 [cité 2025 mars 13];243:15‑8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002914925000384
  24. Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology [Internet] 2024 [cité 2025 mars 13];83:2411‑22. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109724069705
  25. Augusto SN, Issa R, Vanhentenrijk S, Kaelber D, Tang WHW. Sodium Glucose Cotransporter 2 inhibitors in Patients with Amyloidosis With or Without Heart Failure. The American Journal of Medicine [Internet] 2025 [cité 2025 mars 13];S0002934325000920. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002934325000920
  26. Jaiswal V, Hanif M, Jaiswal A, Sundas F, Mattumpuram J, Fonarow G. Abstract 4146158: Sodium-glucose cotransporter 2 inhibitors use and outcomes in transthyretin amyloid cardiomyopathy. Circulation [Internet] 2024 [cité 2025 mars 13];150. Available from: https://www.ahajournals.org/doi/10.1161/circ.150.suppl_1.4146158